Share on StockTwits

Nordion Inc(USA) (NYSE:NDZ) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 215,411 shares, a drop of 87.3% from the April 30th total of 1,693,323 shares, AR Network reports. Based on an average daily trading volume, of 1,077,575 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the company’s shares are short sold.

A number of analysts have recently weighed in on NDZ shares. Analysts at Paradigm Capital raised their price target on shares of Nordion Inc(USA) from $10.00 to $11.75 in a research note on Monday, March 31st. Separately, analysts at Canaccord Genuity downgraded shares of Nordion Inc(USA) from a “buy” rating to a “hold” rating in a research note on Monday, March 31st. They now have a $11.75 price target on the stock, down previously from $12.75. Finally, analysts at CIBC downgraded shares of Nordion Inc(USA) from a “sector perform” rating to a “sector underperform” rating in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Nordion Inc(USA) presently has an average rating of “Hold” and an average target price of $11.75.

Nordion In (NYSE:NDZ) opened at 12.73 on Thursday. Nordion In has a 1-year low of $7.13 and a 1-year high of $12.98. The stock’s 50-day moving average is $12.18 and its 200-day moving average is $10.32. The company has a market cap of $788.1 million and a P/E ratio of 2.83.

Nordion Inc(USA) (NYSE:NDZ) last announced its earnings results on Monday, June 2nd. The company reported $0.22 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.26 by $0.04. The company had revenue of $74.70 million for the quarter, compared to the consensus estimate of $65.25 million. Analysts expect that Nordion In will post $1.22 EPS for the current fiscal year.

Nordion Inc (NYSE:NDZ) is a global health science company, engaged providing products and services used for the prevention, diagnosis and treatment of disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.